Showing 1 posts of 1 posts found.
UCB has partnered with Synosia Therapeutics to develop two of the Swiss firm’s compounds for Parkinson’s disease. Basel-based Synosia has …
MHRA approves first lower-carbon beclometasone inhalers for asthma
Samsung Biologics launches bid to acquire peptide CDMO PolyPeptide
Novogenia breaks ground on personalised healthcare campus
InfectoPharm launches Polish operations with first hospital antibiotic
FibroFind appoints Lee Borthwick as CEO